Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Niraparib in Patients With Advanced Melanoma With Genetic Homologous Recombination (HR) Mutation / Alteration

NCT03925350 is registered in ClinicalTrials.gov with California Pacific Medical Center Research Institute as lead sponsor.

NCT NCT03925350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03925350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Niraparib in Patients With Advanced Melanoma With Genetic Homologous Recombination (HR) Mutation / Alteration
Lead sponsor
California Pacific Medical Center Research Institute
Phase
Phase 2
Overall status
Unknown status
Start date
March 20, 2019
Completion date
February 28, 2023
Enrollment
41 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma